GSK’s Mepolizumab Panel Review May Hinge On Eosinophil Utility In Patient Selection
This article was originally published in The Pink Sheet Daily
With a high regulatory bar for safety and efficacy for new asthma drugs and a skeptical payer base, the significance of and effect on eosinophil counts will be a crucial consideration for the severe asthma candidate.
You may also be interested in...
Should using adult data to label a product for kids be ‘a judgment call?’ Advisory committee asks whether FDA needs more explicit criteria during review of GSK’s Breo Ellipta.
Several antibody drugs are in late-stage development to treat severe asthma and could reach the market in the next two years. But competition for niche subsets of patients will be fierce, and tailoring the right medications to the right patients to justify the higher cost of treatment will require advances in biomarker development.
Pear Therapeutics’ Somryst insomnia treatment tool has become the first FDA-cleared product that was reviewed through the agency’s Software Precertification Pilot Program.